Brazil's Anvisa Approves Yorvipath for Chronic Hypoparathyroidism

Brazil's health regulator Anvisa approved Yorvipath, a parathyroid hormone replacement for chronic hypoparathyroidism, enabling calcium and phosphate regulation. This expands treatment options in Brazil, though market impact is limited to the pharmaceutical sector. The approval follows global regulatory trends but does not signal broader macroeconomic shifts.